Drugs for Hepatitis C: Unlocking a New Mechanism of Action

@article{Bell2010DrugsFH,
  title={Drugs for Hepatitis C: Unlocking a New Mechanism of Action},
  author={T. Bell},
  journal={ChemMedChem},
  year={2010},
  volume={5}
}
  • T. Bell
  • Published 2010
  • Medicine
  • ChemMedChem
The hepatitis C virus (HCV) infects approximately 200 million people worldwide (~3 % of the population), including 4–5 million in the United States. Most are unaware of HCV infections that have not advanced enough to produce liver disease (cirrhosis or liver cancer). Approximately 12 000 Americans are estimated to die from this virus each year. Current treatment, consisting of pegylated interferon-a (PEG-IFN-a) plus the nucleoside antiviral drug ribavirin, is ineffective in more than 50 % of… Expand
Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein.
Hepatitis B and C.
Hepatitis C in children in times of change
Chronic Hepatitis C Infection in Children.
A novel, potent, and orally bioavailable thiazole HCV NS5A inhibitor for the treatment of hepatitis C virus.
Novel benzidine and diaminofluorene prolinamide derivatives as potent hepatitis C virus NS5A inhibitors.
...
1
2
...

References

SHOWING 1-10 OF 16 REFERENCES
Development of novel therapies for hepatitis C.
HCV drug discovery aimed at viral eradication
Identification of Hepatitis C Virus NS5A Inhibitors
HIV-1 protease: mechanism and drug discovery.
[Antiviral drugs].
  • A. Denys
  • Medicine
  • Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • 2011
...
1
2
...